Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns

Inclusion of darunavir and etravirine significantly increased the percentage of patients having at least one fully-active drug from two or three different drug categories. Specifically, this percentage changed from 21% to 44% (two categories) and from 15% to 31% (three categories) (p < 0.001). Interestingly, in the study population, 81 (58%) individuals had no options in the N(t)RTI class. Concerning the other drug classes, 33 (41%) individuals had no available NNRTIs, while 58 (72%) of them had less than two options among the PIs.